Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
1 ビュー
• 08/09/23
0
0
埋め込む
administrator
加入者
Basem William, MD, MRCP, FACP associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive/
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント